These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31339051)

  • 1. Knowledge and awareness of biosimilars among oncology patients in Colorado, USA.
    Ismailov RM; Khasanova ZD; Gascon P
    Future Oncol; 2019 Aug; 15(22):2577-2584. PubMed ID: 31339051
    [No Abstract]   [Full Text] [Related]  

  • 2. Biosimilar Knowledge Among Oncology/Hematology Team Members in Colorado, USA: An Educational Initiative and Follow-Up Survey.
    Ismailov RM; Khasanova ZD
    BioDrugs; 2018 Oct; 32(5):499-506. PubMed ID: 30120705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knowledge and awareness of biosimilars and shared decision-making among gastroenterology team members in Colorado, USA.
    Ismailov RM; Pouillon L; Selinger CP; Khasanova ZD
    Expert Opin Biol Ther; 2021 Jan; 21(1):111-119. PubMed ID: 33107355
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessing biosimilar education needs among oncology pharmacy practitioners worldwide: An ISOPP membership survey.
    Chan A; Patel H; Siderov J; Bubalo J; Foreman E
    J Oncol Pharm Pract; 2020 Apr; 26(3_suppl):11-21. PubMed ID: 32268832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients' information and perspectives on biosimilars in rheumatology: A French nation-wide survey.
    Frantzen L; Cohen JD; Tropé S; Beck M; Munos A; Sittler MA; Diebolt R; Metzler I; Sordet C
    Joint Bone Spine; 2019 Jul; 86(4):491-496. PubMed ID: 30659920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians.
    Cohen H; Beydoun D; Chien D; Lessor T; McCabe D; Muenzberg M; Popovian R; Uy J
    Adv Ther; 2017 Jan; 33(12):2160-2172. PubMed ID: 27798772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A survey of global biosimilar implementation practice conducted by the International Society of Oncology Pharmacy Practitioners.
    Foreman E; Patel H; Siderov J; Harchowal J; Bubalo J; Chan A
    J Oncol Pharm Pract; 2020 Apr; 26(3_suppl):22-32. PubMed ID: 32268828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The development of biosimilars in oncology].
    Jiang SY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):721-725. PubMed ID: 29061013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nursing Roles: Clinical Implications Regarding Trends, Administration, and Education for Biosimilars in Oncology Practice.
    Zack E
    Clin J Oncol Nurs; 2018 Oct; 22(5):21-26. PubMed ID: 30239530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opportunities and challenges in biosimilar uptake in oncology.
    Dolan C
    Am J Manag Care; 2018 Jun; 24(11 Suppl):S237-S243. PubMed ID: 29957909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey.
    Danese S; Fiorino G; Michetti P
    J Crohns Colitis; 2016 Nov; 10(11):1362-1365. PubMed ID: 27112706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survey of pharmacists' knowledge and views of biosimilars in Quebec and France.
    Adé A; Bourdon O; Bussières JF
    Ann Pharm Fr; 2017 Jul; 75(4):267-275. PubMed ID: 28237527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction and commentary: Paving the way for biosimilars in oncology.
    Abraham J
    Semin Oncol; 2013 Dec; 40 Suppl 1():S1-4. PubMed ID: 24267943
    [No Abstract]   [Full Text] [Related]  

  • 14. Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey.
    Chapman SR; Fitzpatrick RW; Aladul MI
    BMJ Open; 2017 Jun; 7(6):e016730. PubMed ID: 28637743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction and commentary: paving the way for biosimilars in oncology, part 2: focus on safety and clinical trial considerations.
    Abraham J
    Semin Oncol; 2014 Feb; 41 Suppl 1():S1-2. PubMed ID: 24560023
    [No Abstract]   [Full Text] [Related]  

  • 16. Education strategy for the implementation of oncology biosimilars essential for operational and patient safety in Alberta, Canada.
    Garg M; Chatterjee A; Chambers CR
    J Oncol Pharm Pract; 2021 Jul; 27(5):1189-1194. PubMed ID: 33896268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey.
    Peyrin-Biroulet L; Lönnfors S; Avedano L; Danese S
    United European Gastroenterol J; 2019 Dec; 7(10):1345-1352. PubMed ID: 31839960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Physicians' Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their Prescribing.
    Karateev D; Belokoneva N
    Biomolecules; 2019 Feb; 9(2):. PubMed ID: 30754705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns.
    Resende HM; Ladislau L; Cardoso ACF; Brandão JDP; Assis BR; Cardoso P; Marassi PHA; Castilho V
    JCO Glob Oncol; 2021 Aug; 7():1316-1324. PubMed ID: 34415791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolution of biosimilars in oncology, with a focus on trastuzumab.
    Nixon NA; Hannouf MB; Verma S
    Curr Oncol; 2018 Jun; 25(Suppl 1):S171-S179. PubMed ID: 29910660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.